Viking Therapeutics, Inc. (VKTX)
NASDAQ: VKTX · Real-Time Price · USD
27.05
-0.53 (-1.92%)
At close: Aug 29, 2025, 4:00 PM
27.14
+0.09 (0.33%)
After-hours: Aug 29, 2025, 7:59 PM EDT
Viking Therapeutics Stock Forecast
Stock Price Forecast
The 13 analysts that cover Viking Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $86.92, which forecasts a 221.33% increase in the stock price over the next year. The lowest target is $30 and the highest is $138.
Price Target: $86.92 (+221.33%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Viking Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 4 | 4 | 4 | 5 | 5 |
| Buy | 5 | 6 | 6 | 6 | 6 | 6 |
| Hold | 1 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 12 | 12 | 13 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $102 | Strong Buy | Reiterates | $102 | +277.08% | Aug 19, 2025 |
| Raymond James | Raymond James | Strong Buy Maintains $125 → $122 | Strong Buy | Maintains | $125 → $122 | +351.02% | Jul 24, 2025 |
| Citigroup | Citigroup | Hold Maintains $31 → $38 | Hold | Maintains | $31 → $38 | +40.48% | Jul 24, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $102 | Strong Buy | Reiterates | $102 | +277.08% | Jun 25, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates $104 | Buy | Initiates | $104 | +284.47% | Apr 28, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
7.31M
EPS This Year
-2.45
from -1.01
EPS Next Year
-3.19
from -2.45
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 97.9M | |||
| Avg | n/a | 7.3M | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.95 | -2.34 | |||
| Avg | -2.45 | -3.19 | |||
| Low | -2.67 | -4.26 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.